Fresenius SE & Co. KGaA Stock

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra 11:35:00 2024-05-31 am EDT 5-day change 1st Jan Change
29.28 EUR +0.86% Intraday chart for Fresenius SE & Co. KGaA +1.21% +4.31%
Sales 2024 * 22.19B 24.06B Sales 2025 * 23.33B 25.3B Capitalization 16.49B 17.89B
Net income 2024 * 1.38B 1.5B Net income 2025 * 1.72B 1.87B EV / Sales 2024 * 1.3 x
Net Debt 2024 * 12.44B 13.49B Net Debt 2025 * 11.7B 12.69B EV / Sales 2025 * 1.21 x
P/E ratio 2024 *
11.8 x
P/E ratio 2025 *
9.38 x
Employees 190,863
Yield 2024 *
3.23%
Yield 2025 *
3.55%
Free-Float 73.04%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Fresenius SE & Co. KGaA

1 day+0.86%
1 week+3.24%
Current month+4.68%
1 month+4.68%
3 months+13.49%
6 months+0.65%
Current year+4.31%
More quotes
1 week
28.72
Extreme 28.72
29.39
1 month
27.26
Extreme 27.26
29.55
Current year
24.32
Extreme 24.32
29.55
1 year
23.93
Extreme 23.93
31.22
3 years
19.69
Extreme 19.69
47.60
5 years
19.69
Extreme 19.69
51.54
10 years
19.69
Extreme 19.69
80.07
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 21-04-11
Director of Finance/CFO 44 18-12-31
Compliance Officer - 23-07-17
Members of the board TitleAgeSince
Director/Board Member 69 15-05-19
Chairman 69 19-12-31
Director/Board Member 63 16-05-12
More insiders
Date Price Change Volume
24-05-31 29.28 +0.86% 2,009,810
24-05-30 29.03 +0.10% 715,062
24-05-29 29 -0.79% 984,889
24-05-28 29.23 +0.10% 843,061
24-05-27 29.2 +0.93% 650,374

Delayed Quote Xetra, May 31, 2024 at 11:35 am EDT

More quotes
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
29.28 EUR
Average target price
36.72 EUR
Spread / Average Target
+25.43%
Consensus